Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

NCT03724747 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

DRUG: BAY2315497 Injection
DRUG: Darolutamide(BAY1841788)

Sponsor

Bayer